The CDC's Respiratory Illnesses Data Channel, updated June 12, 2026, delivered a statement that deserves more attention than it has received: human metapneumovirus (HMPV) is elevated nationally. This surveillance flag appears alongside the parainfluenza (PIV) elevation that has been generating croup-related coverage this week — but HMPV is a distinct pathogen with a different epidemiology, different high-risk populations, and a clinical underdiagnosis problem that is arguably more serious than almost any other respiratory virus in circulation.
Human metapneumovirus was first identified in 2001, making it one of the newer major respiratory pathogens. Despite this, it circulates every year without fail and has established itself as one of the most clinically significant respiratory viruses in human medicine. A major epidemiological study of HMPV published in May 2026 estimated that HMPV is responsible for more than 200,000 hospitalizations in the United States every year — more than influenza B in most seasons, and approaching the hospitalization burden of RSV. Despite this, HMPV is tested for in a small fraction of the patients who likely have it, because most clinical respiratory testing panels — even in emergency departments — include influenza, RSV, and SARS-CoV-2 but frequently do not include HMPV unless specifically requested.
